Abstract | Circadian rhythms are physiological and behavioural cycles generated by an endogenous biological clock, the suprachiasmatic nucleus. The circadian system influences the majority of physiological processes, including sleep-wake homeostasis. Impaired sleep and alertness are common symptoms of neurodegenerative disorders, and circadian dysfunction might exacerbate the disease process. The pathophysiology of sleep-wake disturbances in these disorders remains largely unknown, and is presumably multifactorial. Circadian rhythm dysfunction is often observed in patients with Alzheimer disease, in whom it has a major impact on quality of life and represents one of the most important factors leading to institutionalization of patients. Similarly, sleep and circadian problems represent common nonmotor features of Parkinson disease and Huntington disease. Clinical studies and experiments in animal models of neurodegenerative disorders have revealed the progressive nature of circadian dysfunction throughout the course of neurodegeneration, and suggest strategies for the restoration of circadian rhythmicity involving behavioural and pharmacological interventions that target the sleep-wake cycle. In this Review, we discuss the role of the circadian system in the regulation of the sleep-wake cycle, and outline the implications of disrupted circadian timekeeping in neurodegenerative diseases.
Introduction
Circadian rhythms-physiological and behavioural cycles with a periodicity of approximately 24 h-are generated by an endogenous biological clock, the suprachiasmatic nucleus (SCN). In synchrony with the solar time, the circadian system dictates the 24 h rhythmicity in restactivity behaviour, feeding, body temperature, hormo nal levels and many other biological processes of the organism. Any disruption of this system can, therefore, negatively affect sleep quality, alertness, cognitive perfor mance, motor control, mental health and metabolism. 1 Many of these functions become impaired in neuro degenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD) and Huntington disease (HD), in which several brain areas-including the nuclei involved in circadian and sleep regulation-are affected by neuro degenerative processes. It is not surprising, therefore, that these disorders often entail progressive breakdown of the normal cycles of rest-activity, sleep and alertness; this disruption of circadian rhythms not only contributes to morbidity and poor quality of life, but could also be involved in driving the disease process itself.
In this Review, we provide a brief overview of the cir cadian system, and a comprehensive summary of the current understanding of the function of the circadian system in three common neurodegenerative disorders: AD, PD, and HD.
Human circadian system
Circadian timekeeping is orchestrated by sophisticated molecular loops. The circadian timing system has three distinct components: a pacemaker (SCN), afferent pathways for light and other stimuli that synchronize the pacemaker to the environment, and efferent output rhythms that are regulated by the SCN (Figure 1 ).
The SCN represents the core of the circadian system, and contains approximately 10,000 neurons in mice, and about 50,000 neurons in humans. 2, 3 The SCN is the main clock of the circadian system, and is composed of 'core' and 'shell' subnuclei. Both subnuclei have distinct neuro chemical properties. 4 γAminobutyric acid (GABA) is the main neurotransmitter in nearly all neurons of the SCN; neurons that secrete vasoactive intestinal polypep tide are preferentially distributed in the SCN core, and neurons that secrete arginine vasopressin are located mostly in the SCN shell.
The main afferent pathways emerge from the melanopsin containing retinal ganglion cells and reach the SCN directly via the retinohypothalamic tract, or indirectly via retinogeniculate pathways. 5 The SCN also receives nonphotic information from the raphe nuclei, basal forebrain, pons, medulla and posterior hypothalamus. The main efferents project to the sub paraventricular zone and paraventricular nucleus of the hypothalamus, as well as the dorsomedial hypothalamus, thalamus, preoptic and retrochiasmatic areas, stria ter minalis, lateral septum, and intergeniculate nucleus. In addition, the SCN communicates using humoral signals genes. Furthermore, almost all peripheral tissues, as well as brain regions outside the SCN, contain autonomous circadian clocks. These clocks are influenced by their own distinct circadian synchronizers, but are probably synchronized by SCNmediated messages, or by a direct input from the SCN.
Circadian dysfunction in AD
AD is clinically characterized by a slowly progressive cog nitive decline, with predominant dysfunction in antero grade memory, along with aphasia, apraxia and executive dysfunction. The disease is pathologically defined by the accumulation of amyloidβ (Aβ) peptides in extra cellular senile plaques, and of tau proteins in intracellular neuro fibrillary tangles. 7, 8 These changes lead to neuronal death, spreading from the entorhinal cortex to the hippo campus and surrounding areas and eventually to the neocortex. 9 Circadian rhythm dysfunction is common in patients with AD, and has a major impact on quality of life; it is also one of the most important factors leading to institutionalization of individuals with AD.
10,11
Functional indicators of circadian disruption The circadian disturbances seen in AD are compara ble to the ones seen with normal ageing, but are much more pronounced and severe. Sleep is often highly frag mented, with frequent awakenings. A phase delay of the nocturnal sleep period is a typical indicator of cir cadian rhythm disturbance in AD, and these changes increase with disease duration and progression, 12 often eventually leading to a virtual reversal of the day-night sleep pattern.
Alterations in the periodic changes in the core body temperature have also been described as an indicator of circadian dysfunction in AD. 13, 14 To some extent, these alterations, such as dampening of the amplitude in the 24 h body temperature rhythm, are also seen in normal ageing; however, phase delay, which can be observed in AD, is not seen in normal ageing.
14 A recent study has shown an increase in distal skin temperature during the day in patients with AD, possibly as a result of altered circadian autonomic control. 15 Important information on changes in circadian activ ity has been obtained by wristworn actigraphy devices that enable monitoring of rest-activity patterns. 13, 16, 17 Patients with AD are more active during the night than are healthy controls, which is in line with the clinical picture of fragmented sleep. Changes in rest-activity pat terns correlate with the severity of the dementia; in addi tion, the amplitude of the daily variation in the activity cycle was shown to be diminished in AD. A prospective study in over 1,200 participants demonstrated that these altered activity patterns could predict the development of mild cognitive impairment and/or AD, 18 suggesting that impaired circadian rhythm is a preclinical finding, and might even contribute to the development of demen tia. An actigraphy study in homedwelling patients with early AD showed that whereas participants with mild dementia had activity patterns comparable to healthy controls, participants with moderate dementia showed Figure 1 | A simplified scheme of the circadian system. The timing of human biological rhythms is synchronized to the rotation of the Earth, and is influenced by numerous external and internal time cues. These stimuli are known as 'zeitgebers' (German for 'time giver'). Light is the most important and potent zeitgeber. In addition to light, activity, feeding schedules, and the hormone melatonin also influence circadian timing. This synchronization can become disrupted, which eventually leads to misalignment or internal desynchronization. This loss of coordination of circadian rhythms can have negative consequences for sleep-wake cycles and numerous other biological functions.
a substantially disrupted rest-activity cycle. 19 The most fragmented rhythms were found in institutional ized patients, and within this group, circadian rhythm fragmentation was associated with decreased levels of daytime activity. 17 Activity patterns in humans display a temporal organi zation with socalled scale invariance, meaning that the statistical properties of fluctuations remain similar over different timescales. Such scale invariance was sub sequently demonstrated in rats, and was shown to be critically dependent on the SCN. 20 In healthy older adults, scaleinvariant correlations in activity rhythms decline with age. 21 The greatest reduction in scale invariance-similar to that seen in experimental animal models with SCN lesions-has been found in patients with latestage AD.
Neuroendocrine and neuropathological markers
The dynamics of melatonin secretion in AD have been studied extensively. Reductions in total melatonin levels are more profound in AD than in normally ageing indi viduals. [22] [23] [24] In a postmortem study, a marked decrease in cerebrospinal fluid melatonin levels was found in patients with AD; 25 furthermore, the rhythmicity in melatonin secretion disappeared at the early-possibly already pre clinical-stage of the illness, 26, 27 and the pattern became very irregular. 28 Postmortem studies have demonstrated a region specific reduction in histidine decarboxylase mRNA levels in the tuberomammillary nucleus of patients with AD, 29 and diurnal expression of this histamine produc tion ratelimiting enzyme was found to be reduced in neurodegenerative disease. 30 Several lines of research indicate the SCN is directly affected by the pathophysiological processes that under lie AD. Atrophy of the SCN, involving both volume reduction and decreased total cell count, has been dem onstrated. 2 The number of neurons in the SCN that express melatonin receptor type MT1 decreases in late stage AD, but not in the earlier disease stages. 31 Besides loss of neurons, neurofibrillary tangles were observed in SCN neurons in patients with severe AD, even though amyloid plaques were scarce in this region. 32 Within the SCN, neurons that express vasoactive intestinal polypep tide (VIP), arginine vasopressin (AVP) or neurotensin have been shown to be depleted in AD. [32] [33] [34] [35] Consequently, AVP levels are strikingly lower in AD, and vasopressin mRNA levels are already decreased in the preclinical stage of AD-these findings are thought to be related to the disappearance of the normal diurnal rhythm. 34 Importantly, progression of AD neuropathology corre lates with increased circadian dysfunction, indicating a functional link between the two. 12 
Chronogenetics
The 'chronogenetics' of AD is complex, and our under standing of it is still in its infancy. The genetic underpin nings of circadian system disruption in AD are discussed in more detail elsewhere. 36 Although AD pathology seems to affect the pineal gland only to a limited degree, 37 melatonin secretion is disrupted and the diurnal pattern in the expression of the clock genes ARNTL, PER1 and CRY1 is lost in the pineal gland of patients with AD. 38 The periodic fluctuations in the expression of several clock genes are preserved in brain regions outside the SCN in patients with AD, 39 but abnormalities have been found in both the phase of the clock gene rhythms and the phase relationships between brain regions. These alterations reflect the disruption of the 'master control' by the SCN.
Circadian dysfunction in animal models
Precise assessment of circadian parameters (such as circadian period length) in patients with AD is virtu ally impossible due to difficulties in applying experi mental designs such as constant routine studies in this population. Animal models of AD are useful, there fore, to disentangle the mechanisms responsible for circadian dysfunction.
The tripletransgenic (3xTg) mouse model con tains three mutations that have been associated with AD in humans (APP LysMet670-671AspLeu, MAPT Pro301Leu and PSEN1 Met146Val). In line with post mortem findings in patients with AD, the 3xTg mouse model exhibits decreased numbers of AVP and VIP neurons in the SCN. 40 In addition, circadian patterns of locomotor activity are altered: nocturnal activity is decreased and daytime activity is increased, and the mice have shorter freerunning periods (circadian rhythms not entrained to external time cues). These alterations were observed even before the onset of AD pathology. 40 The 3xTg mice also showed agedependent changes in core body temperature rhythms (phase advance and increased mean body temperatures) similar to those seen in healthy older adults. 41 Mice that were transgenic only for human APP (Tg2576) showed no changes in circadian activity rhythms; 42 however, marked exten sion of thefree running period was seen, although normal entrainment by light remained possible. 43 A mouse model with gross overexpression of human APP (TgCRND8), considered to be a model for 'aggressive amyloidosis' with widespread plaque formation, exhib ited disorganization of diurnal activity even before the emergence of AD pathology. 44 Circadian dysfunction and AD pathology So far, we have discussed circadian disruption as a con sequence of AD; however, increasing evidence suggests that circadian and/or sleep dysfunction can aggravate AD pathology, indicating a reciprocal relationship between the two. Evidence that the sleep-wake cycle influences amyloid dynamics, 45 and the possible neuroprotective effects of melatonin, one of the most important circadian regulators, support this hypothesis. 46 The bidirectional interaction between sleep and AD pathology has been discussed in detail elsewhere. 47 Mouse experiments showing that sleep deprivation resulted in a marked increase in Aβ accumulation led to the exciting hypothesis that disrupted sleep could be a causal contributor to the development of AD. 48 In 2013, sleep was shown to contribute to the clearance of metabo lites such as Aβ from the brain in mice. 49 More recently, sleep deprivation has been shown to increase Aβ levels in healthy humans. 50 These experimental data are backed by several epidemiological studies showing that sleep restriction increases the risk of cognitive impairment. 47 Several in vitro and animal model studies have assessed the potential antioxidant, neuroprotective and anti amyloidogenic effects of melatonin These studies have been extensively reviewed recently. 23, 24 Melatonin inhib its the formation of βsheets and amyloid fibrils, 51 and analysis of mouse brain extracts revealed that treatment with melatonin leads to a modest reduction in cortical APP and Aβ levels. 52 Treating Tg2576 mice with mela tonin at an early age reduced the expected agerelated increase in Aβ concentrations and, more importantly, increased survival. 53 Treatment of circadian dysfunction in AD A number of doubleblind controlled trials and several openlabel studies have shown that melatonin can improve sleep quality and reduce sundowning. [54] [55] [56] [57] However, a large doubleblind, randomized, placebo controlled trial in 157 patients with AD failed to show a beneficial effect of melatonin on sleep patterns meas ured by actigraphy. 58 Another recent study also found no effects of melatonin on agitation, sleep or circadian rhythms in AD. 59 These negative findings are in line with an earlier metaanalysis, which found no significant effects of melatonin on cognitive impairment. 60 Several controlled trials have shown that bright light therapy can improve sleep quality and restore diurnal activity rhythms in patients with dementia. [61] [62] [63] [64] In two other studies, light therapy was found to stabilize diurnal activity rhythms without direct effects on sleep quality. 65, 66 Circadian dysfunction in PD PD is the second most common neurodegenerative dis order after AD. 67, 68 The cardinal features of PD result from degeneration of dopaminergic neurons within the substantia nigra, and include tremor, bradykinesia, rigid ity, and gait impairment. Other neurotransmitter systems are also affected, and are responsible for numerous nonmotor manifestations of PD.
A growing body of evidence suggests alterations of the circadian system in PD. 69, 70 Dopamine is a neuro transmitter of major importance at several levels of the circadian system, and its metabolism and signalling activity are strongly influenced by the circadian clock, as reviewed elsewhere. 71 Impaired circadian function in PD is implicated not only in dysregulation of the sleep-wake cycle, but also in autonomic, cognitive, psychiatric and motor manifestations of the disease.
Diurnal clinical fluctuations
Numerous studies have reported that the behaviours, symptoms and signs associated with PD, such as dis ruptions in motor activity, [72] [73] [74] [75] autonomic function, [76] [77] [78] sleep-wake cycles [79] [80] [81] and visual performance, 82 as well as responsiveness to dopaminergic treatments, 72, 83 show diurnal fluctuation. These observations suggest circadian influences on the expression of clinical features of PD.
Fluctuations of motor symptoms in PD are very common. Actigraphy studies demonstrate lower peak activity level and lower amplitude of the rest-activity cycle in patients in PD than in healthy older adults. 80, 81 Increased physical activity and shorter periods of immo bility during the night result in an almost flat diurnal pattern of motor activity in PD. 84 Patients with PD also have a more fragmented pattern of activity, with transi tions from highactivity to lowactivity periods, leading to lesspredictable rest-activity rhythms than are seen in healthy older people. 85 In both stable patients with PD and those with 'wearing off ' phenomena, motor symp toms tend to be more prominent in the afternoon and evening. 72, 83 This daily pattern seems to be independent of the timing of dopaminergic medications, and could be related to circadian regulation of dopaminergic systems. In support of this notion, the responsiveness of PD motor symptoms to dopaminergic treatments declines through out the day, despite the absence of significant changes in levodopa pharmacokinetics. 72 Alterations in the circadian regulation of the auto nomic system have also been reported in PD. 24 h ambu latory blood pressure monitoring in patients with PD demonstrates reversal of the normal circadian rhythm of blood pressure, increased diurnal blood pressure vari ability, postprandial hypotension, and high nocturnal
Figure 2 | Molecular organization of the circadian system. The proteins encoded by the core set of clock genes-PER, CLOCK, ARNTL (also known as BMAL1) and CRY-interact to create a self-sustaining negative transcription-translation feedback loop. 171 The intracellular level of CLOCK remains steady throughout the 24 h period. The high level of ARNTL at the beginning of the day promotes the formation of ARNTL-CLOCK heterodimers, which in turn activate transcription of PER and CRY. As PER accumulates in the cytoplasm, it becomes phosphorylated and degraded by ubiquitylation. CRY accumulates in the cytoplasm late in the subjective day, and translocates to the nucleus to inhibit ARNTL-CLOCK-mediated transcription. At night, the PER-CRY complex is degraded, and the cycle starts again. This feedback loop ensures a high level of ARNTL and low levels of PER and CRY at the beginning of a new circadian day. blood pressure; 86, 87 Holter electrocardiographic monitor ing reveals a decrease in sympathetic activity during the day, combined with loss of circadian heart rate variability and disappearance of the sympathetic morning peak. 88 These abnormalities could arise within the peripheral autonomic ganglia, but the central networks, including the hypothalamus, might also be involved. 89, 90 Circadian fluctuations in visual performance, as meas ured by contrast sensitivity, are altered in PD. 82 Impaired regulation of retinal dopamine, which exhibits an endo genous circadian rhythm that is independent of lightdark cycles, is most likely to be responsible for these changes. 91 Because circadian changes in contrast sensitiv ity can occur independently of circadian oscillations in motor symptoms, it is possible that the retina, striatum, cortex and other anatomical networks involved in visual processing can have differential threshold responses to the circadian signalling of dopamine. 92 Sleep disturbances are among the most common and disabling nonmotor symptoms of PD, and affect as many as 90% of patients. 93 The impact of circadian dysregu lation on sleep and alertness in the PD population has not been systematically assessed. The aetiology of sleep disturbance is likely to be multifactorial, and to include the effects of PDassociated motor features on sleep, adverse effects of antiparkinsonian medications, and neuro degeneration of central areas that regulate sleep, such as the raphe nucleus and locus coeruleus; this degeneration is likely to underlie sleep impairment that emerges before the onset of the motor symptoms of PD. 94 
Markers of circadian function
Only a few studies have attempted to identify markers of circadian function in PD. In a cohort of 26 individu als with PD, patients-with or without motor complica tions-who were treated with dopaminergic agents had a decreased amplitude of melatonin fluctuation, and the phase of secretion was advanced in comparison with recently diagnosed patients who were not yet receiv ing treatment. 95 These results suggest a trend toward a shift in the phase and a reduction in the amplitude of melatonin secretion during the evolution of PD, and emphasize a need to investigate the effects of dopamin ergic medication of circadian function. Circadian fluc tuation of body temperature and plasma cortisol did not differ between the groups in this study. In another study, melatonin secretion in nine patients with recently diag nosed PD was similar to healthy controls. 96 In a study of 12 patients with PD, 24 h mean cortisol production rate was higher and the mean secretory cortisol curve was flatter-indicating reduced diurnal variation-in the PD group than in the control group. 97 In a small study of eight recently diagnosed patients who were not receiving medication, no significant alterations were found in diurnal secretion profiles of growth hormone, thyrotropin and prolactin. 98 24 h rhythms of core body temperature are preserved in PD, 99 but basal body temperature is lowered in patients with parkinsonian symptoms. 100 Patients with PD and comorbid depression exhibit altered circadian rhythms of rectal temperature and decreased amplitudes of core body temperature. 101 Although these investigations suggest altered circa dian rhythmicity in PD, they should be interpreted with caution due to small sample sizes and study designs that reflect influences of both endogenous circadian and exogenous (light exposure, physical activity, meals, social schedules) rhythms on PD.
In a recent study that employed a modified constant routine experimental protocol in 20 patients with mild to moderate PD and 12 agematched controls, significant blunting of the circadian rhythm of melatonin secretion and reduced amplitude of the melatonin rhythm was observed. 102 Patients with excessive daytime somnolence had a particularly prominent reduction of the melatonin rhythm amplitude. In another study, notable reductions in the amplitude of melatonin secretion were also dem onstrated in patients with de novo PD. 103 In contrast to these findings, an additional study reported a threefold increase in melatonin secretion in a cohort of medicated patients with PD. 104 Although further investigations are needed to confirm the role of neurodegenerative changes in disruption of circadian function, these observations support a role for circadian disruption in excessive daytime sleepiness associated with PD.
Several studies have demonstrated robust oscillatory patterns in the of core clock genes in human whole blood and peripheral blood mononuclear cells, [105] [106] [107] demon strating the feasibility of using clock gene expression as a marker of circadian function. In a study of 17 individuals with PD and 16 agematched controls, the relative abun dance of the clock gene ARNTL was notably lower during the night in patients with PD than in controls. Expression levels of ARNTL correlated with PD severity, as assessed by Unified PD Rating Scale scores (UPDRS). 108 The lack of diurnal variation in ARNTL expression was recently confirmed in another study. 103 
Circadian entrainment
Numerous studies have demonstrated beneficial effects of supplemental widespectrum bright light therapy on sleep quality, daytime sleepiness, mood and quality of life in healthy elderly individuals and patients with dementia. Several lines of evidence provide a ration ale for exploring supplemental light exposure in PD. For example, dopamine is a probable mediator of light signalling to the retinal circadian clock that provides direct input to the SCN. 109 Exposure to light facilitates the recovery of motor function in an experimental rat model of chronic PD. 110 To date, only a few exploratory studies have exam ined the effects of bright light in patients with PD. In a case series of 12 patients, daily evening exposure to sup plemental bright light of 1,000-1,500 lux improved sleep quality and mood, as well as bradykinesia and rigidity. 111 Similar beneficial effects of supplemental bright light on sleep, mood, anxiety and motor performance were reported in an openlabel retrospective study of 129 levodopatreated patients followed up for 8 years. 112 In another study, exposure to bright light of 7,500 lux was associated with improvements in UPDRS part I, II and IV scores, and alleviated daytime sleepiness. 113 Although these studies demonstrated good feasibility and positive effects of bright light therapy on nonmotor and motor manifestations of PD, further validation studies involv ing larger cohorts and employing objective outcome measures are needed.
Circadian dysregulation in animal models
Animal models of PD provide an opportunity to further explore the functioning of the circadian system in PD and to address questions that cannot be investigated within the clinical research protocols in the PD popula tion. Primates treated with the neurotoxin 1methyl4 phenyl1,2,3,6tetrahydropyridine exhibit immediate disruption of the rest-activity rhythms, alterations in rapid eye movement (REM) sleep, and increased daytime sleepiness. [114] [115] [116] In rats, dopaminergic depletion induced by bilateral striatal injection of 6hydroxydopamine (6OHDA) results in disturbances of circadian rhythms of heart rate, temperature and locomotor activity. [117] [118] [119] In addition to disruption of behavioural rhythms, dopaminergic depletion induced by 6OHDA has been demonstrated to be followed by blunting of diurnal fluc tuation in the expression of the clock gene PER2 in the striatum. 120 A mouse model overexpressing αsynuclein, a protein that has been implicated in the neuropathology of PD, exhibits altered circadian rest-activity rhythms and reduced daytime neuronal firing rate in the SCN. 121 Animal models of circadian disruption in PD have been reviewed in more detail elsewhere. 122 
Circadian dysfunction in HD
HD is a fatal autosomal dominant neurodegenerative condition that affects approximately 14-16 individu als per 100,000, 123 and typically becomes manifest in midlife. 124 The disease is caused by abnormal expansion of the trinucleotide CAG repeat 125 in exon 1 of the hun tingtin gene (HTT), 126 leading to ubiquitous expression of mutant HTT. [126] [127] [128] HD is characterized by progres sively worsening motor and nonmotor deficits, including cognitive abnormalities that eventually lead to demen tia, 129 neuropsychiatric disorders, 130 weight loss, 131 and severe sleep [132] [133] [134] [135] [136] [137] and circadian disturbances.
138,139
Limitations and potential for research Clinical experience and epidemiological and experimen tal data all indicate that the circadian system is affected in HD; however, patient data are limited. This lack of data could be attributable to the relatively low incidence of HD in the general population, and the methodologi cal challenges of putting patients who exhibit complex combinations of motor, cognitive and psychiatric fea tures through relatively intense protocols for circadian and sleep research. Furthermore, sleep problems in HD tend to go undiagnosed by physicians and underreported by patients, possibly due to a lack of insight or perceived relative unimportance of sleep problems when compared with the motor, cognitive and affective features that are recognized as key features of this disorder. In spite of these limitations, the study of patients with HD has great research potential by virtue of the genetic basis of the disease, which enables the identification and followup of premanifest individuals, and the ability to predict disease onset. These factors create a unique opportunity to investigate and establish causality between the pre morbid structural and functional degeneration of the brain and the clinical features, including circadian and sleep disruption. Such longitudinal studies could aid in elucidating the role of the circadian system and sleep behaviour in normal physiological processes, as well as in other neurodegenerative disorders.
Another important research opportunity in HD stems from the ability to make transgenic animal models of the disease. These models, especially mice, can recapitulate many of the main features of HD, and have been essen tial to our current understanding of the role of sleep and circadian disturbances in the condition. A need exists, however, for detailed prospective observational and inter ventional sleep and circadian studies in HD to confirm that the deficits reported in these animals are relevant for human disease.
Sleep-wake timing and sleep quality Delayed sleep-wake timing and diurnal preference have been repeatedly linked to mental health problems, in particular depression. 140 Depression is a major problem in HD, along with apathy, anxiety and irritability. 141 In a focused questionnairebased sleep survey, wakeup time was markedly delayed in patients with manifest HD as compared with both premanifest mutation carriers and noncarrier controls, but no differences in bedtimes were observed. 142 Selfreported sleep quality was also con siderably reduced in the patients with manifest disease, whereas premanifest mutation carriers had intermediate sleep quality. These findings were confirmed in another cohort of manifest patients and premanifest mutation carriers; moreover, the later wakeup times were nega tively associated with cognitive scores and total func tional capacity, and positively associated with depressive symptoms. The degree of sleep phase delay in premani fest mutation carriers was intermediate between that of HD patients and controls. 143 In line with the self reports, a small polysomno graphy study involving nine patients with earlystage HD showed reduced sleep efficiency and increased time spent in bed, although the authors did not report whether this latter finding was due to an earlier bedtime or to a delayed getup time. 132 Another polysomnography study, however, reported that sleep onset before 9 pm was much more frequent in manifest and premanifest HD than in controls. 137 According to a large questionnaire based community survey, sleep problems were highly prevalent (>87%) among the 292 individuals with HD, with early waking time being the most important sleep complaint. 144 Several other studies have shown that selfreported daytime sleepiness and sleep complaints are more prevalent in patients with HD than in con trols. 142, 143, 145 although it is not known how these sub jective sleep reports relate to the objective measures of vigilance and sleep quality. The earliest objective sleep study using polysomnography was published in 1967 146 as a case report on a 25yearold patient with HD who showed suppression of rapid eye movements during REM sleep as an early symptom. A later study, published in 1985, described increased sleep latency, worse sleep efficiency and interspersed wakefulness in a small cohort of patients with HD. 133 The few subsequent polysomno graphy studies have confirmed these findings; 132, [135] [136] [137] 147 in addition, decreased slowwave sleep, 135, 136, 147 REM sleep disturbances 132, 135, 137 and an increased number of sleep spindles have been documented. 134, 147 Rest-activity rhythms The initial continuous actigraphic assessments in patients with HD aimed to examine involuntary move ments in the daytime, rather than the rest-activity cycle, as a core feature of HD. Despite the presence of chorea, these studies reported a decreased level in daytime activ ity 148, 149 that correlated with disease penetrance. 149 In another study, patients with mild to moderate disease exhibited a robust increase in total and maximal activ ity and spent longer times performing highacceleration movements while they were awake compared with con trols. These patients also showed more overnight activity than did the control individuals. 150 The first study that employed actigraphy specifically to assess circadian rest-activity rhythms in patients with HD found evidence of increased nocturnal activity, while daytime activity remained similar to controls. The increased activity during the nighttime was primarily driven by having a sleep-rest period interspersed with activity bouts, and could not have been caused by the involuntary movement disorder, which subsides during sleep. 138 These results are reminiscent of the subjective and objective sleep reports in patients with HD, which show an increased number of awakenings and an overall decrease in sleep quality. 132, 133, [135] [136] [137] 142, 143, 147 Rest-activity rhythms in animal models of HD The genetic basis of HD enables the generation of trans genic models of disease that can recapitulate many of the main features of HD 151 and, despite fundamen tal interspecies differences in sleep-wake behaviour, studies of circadian function in these animal models have helped us to understand the basis and progres sion of circadian rhythm disruption in HD. In the early stages of disease, the diurnal rest-activity cycle is fairly well conserved, and becomes increasingly disrupted as the disease progresses, with total disintegration in endstage disease. 138, 139, [152] [153] [154] [155] [156] [157] [158] This circadian disruption depends not only on age but also on gene dose:
159 the rest-activity disorganization becomes more prominent in animals that are homozygous for the mutation than in heterozygotes. The homozygotes also exhibited a more severely abnormal circadian behavioural response to light, and a steeper decline in locomotor rhythms. 159 Interestingly, in a transgenic sheep model of HD, the circadian abnormalities also depend on social factors: abnormalities of circadian behaviour emerged in sheep kept in an 'HDonly' flock, whereas the behaviour of HD sheep kept mixed with nontransgenic sheep remained relatively normal. 152 In most studies, the circadian disruption is associated with progressive impairment of sleep architecture and sleep EEG 153, 154, 156, 157 suggesting an interaction between disruption of circadian behaviour and fragmented sleep architecture, but with no exact indication on any causal relationship between the two. Restoration of circadian rhythmicity and sleep has been shown to alleviate the disease course in HD: reconsolidation of circadian entrainment by pharmacological agents or other inter ventions slows down cognitive decline and normalizes circadian gene expression. [160] [161] [162] [163] These effects are likely to be modulated by sex and genotype. 163 The central circadian pacemaker Surprisingly few data are available on the integrity and function of the SCN in patients with HD. One study that measured blood melatonin reported that although patients with HD had similar overall melatonin concen trations to healthy controls, they displayed a delayed melatonin secretion rhythm, and the severity of the delay correlated with impairments in motor and other func tions. 164 More recently, blood melatonin was shown to be already decreased in premanifest patients, with manifest patients having a more marked reduction. In both mani fest and premanifest HD, timing of melatonin secretion onset was much more variable than in controls. 165 Several studies have found altered levels of cortisol in blood and urine in HD. 152, 160, 166, 167 Furthermore, changes in the pattern of pulsatile release of adrenocorticotropic hormone, followed by increased pulsatile secretion of cortisol, correlated with CAG repeat size and could, thus, be caused directly by the central HD pathology rather than being secondary to any neuropsychiatric disease. 167 The VIPcontaining cells of the SCN probably help to regulate cortisol secretion by inhibiting its release, 168 and postmortem studies in patients with HD have revealed loss of VIP and AVP expression within the SCN. 169 This decrease in VIP levels has also been associated with circadian disruption in transgenic animal models. 155 Besides the progressive circadian disruption of the rest-activity rhythm in transgenic animal models of HD, progressive disruption of circadian patterns of body tem perature and heart rate has been found. 139 One study in a mouse model of HD reported abnormal cellular gene expression in the SCN and several other brain regions, indicative of dysfunction of the genetic underpinnings of the molecular clock, 138 but other studies reported no change in expression of the genes associated with this clock. 139, 159 The former study connected the impaired cir cadian rhythm to spontaneous electrical activity of SCN neurons, suggesting that the electrical activity within the central clock itself could be altered by the disease. 139 However, in vitro studies have described normal elec trophysiological output and endogenous rhythms of circadian gene expression in the SCN, indicating that in vivo circadian disturbances in transgenic mice might be caused by abnormalities in the afferent pathways to the SCN. 161 This idea is further supported by the nor malization of circadian gene expression in vivo after reentrainment of circadian rhythms by behavioural interventions in a transgenic mouse model of HD, 161 although the study provided no direct evidence for normal electrophysiological activity of the SCN in vivo. Experimentally induced mitochondrial dysfunction leads to striatal lesions and can also contribute to sleep and/or circadian dysfunction, suggesting a mechanistic link that is relevant to HD. 170 In summary, although reports from patients and trans genic animal models are inconsistent, there is convincing evidence for major disruption of the circadian system in HD. This might be reversible, and could provide a strategy to slow down the disease process.
Conclusions
The circadian system controls a wide range of physio logical and behavioural processes and coordinates their synchronicity. Increasing evidence shows suggests that the circadian rhythms are dysregulated in neurodegen erative disorders. In this Review, we have highlighted the literature that spans clinical and animal studies of circadian function in three common neurodegenerative disorders: AD, PD and HD. While each of these dis orders has its distinct phenotype-genotype signature, each also exhibits overlapping symptoms that could, at least in part, be based on circadian dysfunction. One of the best examples is disruption of the sleep-wake cycle, which represents one of the most robust output rhythms of the circadian system. Both human and animal studies have documented disruption of circadian timekeep ing from physiological, molecular and behavioural perspectives in these three disorders. Impairments in circadian timekeeping are likely not only to influence regulation of sleep and alertness, but also affect mood, cognition, autonomic function and motor function in these disorders.
One of the key questions that remains unanswered is whether circadian disruption associated with neuro degeneration represents one of its consequences, or whether it could be one of the causative factors leading and/or contributing to the neurodegenerative cascade. In the future, longitudinal studies aimed at simultan eously examining circadian function and other disease manifestations throughout the course of these disorders will be critical in attempting to answer this question. These studies should include premanifest carriers of the HD mutant allele, individuals carrying mutations that increase the risk of AD, and individuals at high risk of development of PD, such as those with REM sleep behaviour disorder.
Regardless of whether circadian disruption represents a cause or a consequence of neurodegeneration, we argue that AD, PD and HD share 'chronodegeneration' as a common feature. This is an important notion, as inter ventions directed at normalizing circadian rhythmicity in these disorders might provide novel opportunities for muchneeded therapies. These therapies could not only improve symptoms and quality of life, but also slow down disease progression. The circadian system, there fore, could be a new diagnostic and therapeutic target in neurodegenerative disorders.
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